文献速递腹部技术与安全CT

基线CT体成分预测免疫治疗转移性结直肠癌预后的临床影像模型

A clinico-radiological model integrating baseline CT-derived body composition to predict prognosis in immunotherapy-treated metastatic colorectal cancer.
PubMed 文献 · Eur J Radiol · 2026-06-12

本研究回顾性纳入107例接受免疫检查点抑制剂治疗的转移性结直肠癌患者,在第三腰椎水平分割基线腹部CT,量化内脏脂肪面积、皮下脂肪面积、骨骼肌面积及骨骼肌放射密度。通过多因素与LASSO Cox回归筛选独立预后因素并构建列线图,内部验证后C指数为0.733,预测6个月无进展生存期的AUC为0.842。

要点

  • 基线内脏脂肪面积和骨骼肌放射密度较高者无进展生存期更长。
  • 高内脏脂肪面积的保护效应在基线肝转移患者中更明显。
  • 列线图预测6个月无进展生存期的AUC为0.842。

核心结论

  • 基线VFA和SMD是接受免疫治疗的转移性结直肠癌患者潜在独立预后生物标志物。
  • 所建临床-影像列线图对无进展生存期具有较好的预测准确性。

研究设计与样本

  • 回顾性研究,纳入107例接受免疫检查点抑制剂治疗的转移性结直肠癌患者。
  • 在第三腰椎水平分割基线腹部CT图像,量化VFA、SFA、SMA和SMD。
  • 采用单因素、多因素Cox回归及LASSO筛选PFS独立预后因素。
  • 通过C指数、时间依赖性ROC曲线、校准曲线及决策曲线分析评估列线图性能。

关键影像表现/征象

  • 基线腹部CT第三腰椎层面可见内脏脂肪面积和骨骼肌放射密度的个体差异。
  • 高内脏脂肪面积与高骨骼肌放射密度患者表现出更长的无进展生存期。

诊断标准与关键数值

  • 基线VFA和SMD为经多因素及LASSO Cox回归确认的无进展生存期独立预后因素。
  • 高VFA与高SMD均与无进展生存期延长显著相关。
  • 列线图经1000次自助重抽样内部验证后,乐观校正C指数为0.733。
  • 预测6个月无进展生存期的时间依赖性AUC为0.842,95%CI为0.761-0.923。

临床应用与阅片要点

  • 阅片时可关注第三腰椎层面内脏脂肪面积和骨骼肌放射密度,作为免疫治疗前的基线风险信息。
  • 对存在肝转移的患者,内脏脂肪面积较高提示相对更好的无进展生存期。

局限性

  • 研究为回顾性设计。
  • 列线图仅进行内部验证,未报告外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aims to investigate the association between baseline CT-derived body composition parameters and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) receiving immunotherapy, and to develop a personalized clinico-radiological prognostic model.

MATERIALS AND METHODS: We retrospectively enrolled 107 mCRC patients treated with immune checkpoint inhibitors. Baseline abdominal CT images at the third lumbar vertebra were segmented to quantify visceral fat area (VFA), subcutaneous fat area (SFA), skeletal muscle area (SMA), and skeletal muscle radiodensity (SMD). Independent prognostic factors for PFS were identified via univariable and multivariable Cox regression analyses and further validated using the Least Absolute Shrinkage and Selection Operator (LASSO). Exploratory subgroup interaction analyses were conducted to evaluate prognostic consistency. Finally, a predictive nomogram was developed and performance was assessed via C-index, time-dependent receiver operating characteristic (ROC) curves, calibration plots with 1000 bootstrap resamples, and decision curve analysis (DCA).

RESULTS: Multivariable and LASSO Cox regression analyses identified age, number of metastatic organs, baseline CA 19-9 level, VFA, and SMD as potential independent prognostic factors for PFS. Higher VFA and SMD were significantly associated with prolonged PFS. Notably, subgroup analyses revealed that the protective effect of high VFA was more evident in patients with baseline liver metastasis (P for interaction < 0.05). After internal validation with 1000 bootstrap resamples, the optimism-corrected C-index was 0.733 after optimism correction. The time-dependent area under the curve (AUC) for predicting 6-month PFS was 0.842 (95 % CI: 0.761-0.923). Calibration curves demonstrated good agreement between nomogram-predicted probabilities and actual observed survival outcomes. DCA suggested potential clinical net benefit of the developed nomogram.

CONCLUSION: Baseline VFA and SMD are potential independent prognostic biomarkers for mCRC patients undergoing immunotherapy. The proposed clinico-radiological model may offer promising predictive accuracy for PFS, help personalized risk stratification and clinical decision-making.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Liu, Xu, Miao, et al. A clinico-radiological model integrating baseline CT-derived body composition to predict prognosis in immunotherapy-treated metastatic colorectal cancer. Eur J Radiol. 2026. PMID: 42289152. doi:10.1016/j.ejrad.2026.113000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。